Hypersensitivity to dihydroartemisinin and piperaquine phosphate. Severe renal damage or liver disease. Blood disorders. Severe malaria according to WHO definition, drugs that prolong the QTc interval, symptomatic cardiac arrhythmias, severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle ejection fraction, electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia. Pregnancy.